Angela Zubel, chief development officer, Debiopharm, discusses why 2026 marks a shift from AI pilots to broader operational ...

From antibiotic resistance to emerging viral threats, the global demand for new medicines is intensifying, yet traditional drug discovery pipelines remain slow and expensive. A new scientific review ...

Recent developments in the biopharma AI world include an alliance between Thermo and Datavant, plus news from Insilico, ...

And there's more than one way to monetize this technology.

On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...

The Administration for Strategic Preparedness and Response has launched a $100 million competition to support the development of antiviral drug therapies targeting viruses in the Togaviridae and ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.

Organotics, a brain organoid startup, uses AI and patient-derived brain models to fast-track personalized medicine for autism and reduce psychiatric drug failure.

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...

A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...